Abstract
Inflammation is a risk factor for cancer development in several tissues. In the colorectum, inflammatory bowel disease (ulcerative colitis and Crohn’s disease) is a longstanding inflammatory disease with increased risk for colorectal cancer (CRC). Several molecular events involving in chronic inflammatory process contribute to multi-stage carcinogenesis of CRC in the inflamed colon. They include alterations in production of reactive oxygen and nitrogen species, upregulation of pro-inflammatory cytokines and inflammatory enzymes, and intestinal immune system. In this short review, experimental animal models of inflammation-associated CRC are described. Also, some preclinical data on chemoprevention of inflammation-associated CRC by astaxanthin and a specific inhibitor of nitric oxide synthase using these inflammation- related -CRC models is briefly introduced.
Keywords: Inflammation and cancer, inflammatory bowel disease, colorectal cancer, chemoprevention, animal model
Current Drug Targets
Title:Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study
Volume: 13 Issue: 14
Author(s): Takuji Tanaka
Affiliation:
Keywords: Inflammation and cancer, inflammatory bowel disease, colorectal cancer, chemoprevention, animal model
Abstract: Inflammation is a risk factor for cancer development in several tissues. In the colorectum, inflammatory bowel disease (ulcerative colitis and Crohn’s disease) is a longstanding inflammatory disease with increased risk for colorectal cancer (CRC). Several molecular events involving in chronic inflammatory process contribute to multi-stage carcinogenesis of CRC in the inflamed colon. They include alterations in production of reactive oxygen and nitrogen species, upregulation of pro-inflammatory cytokines and inflammatory enzymes, and intestinal immune system. In this short review, experimental animal models of inflammation-associated CRC are described. Also, some preclinical data on chemoprevention of inflammation-associated CRC by astaxanthin and a specific inhibitor of nitric oxide synthase using these inflammation- related -CRC models is briefly introduced.
Export Options
About this article
Cite this article as:
Tanaka Takuji, Animal Models of Carcinogenesis in Inflamed Colorectum: Potential Use in Chemoprevention Study, Current Drug Targets 2012; 13 (14) . https://dx.doi.org/10.2174/138945012804545452
DOI https://dx.doi.org/10.2174/138945012804545452 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Coronary Circulation in Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Can Marine Omega 3 Fatty Acids Prevent and/or Treat Metabolic Syndrome?
Current Nutrition & Food Science Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Regulation of Inflammation and Myocardial Fibrosis in Experimental Autoimmune Myocarditis
Inflammation & Allergy - Drug Targets (Discontinued) Reperfusion Therapies in Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Transcriptional and Non-transcriptional Regulation of Glucose Metabolism and Insulin Sensitivity through Vitamin D
Current Nutrition & Food Science Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Current Medicinal Chemistry Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets New Trends in Anti-Atherosclerotic Agents
Current Medicinal Chemistry Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Fenofibrate and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Control of Blood Pressure in the Community: An Unsolved Problem
Current Pharmaceutical Design Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology Drug Eluting Coronary Artery Stents
Current Drug Delivery